Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho Sells 4,695 Shares of Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho sold 4,695 shares of the stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $8.98, for a total transaction of $42,161.10. Following the sale, the general counsel now owns 204,076 shares of the company’s stock, valued at approximately $1,832,602.48. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Scholar Rock Trading Down 3.3 %

Shares of NASDAQ SRRK opened at $8.49 on Wednesday. Scholar Rock Holding Co. has a 1 year low of $5.93 and a 1 year high of $21.17. The firm’s 50-day moving average is $12.35 and its 200-day moving average is $14.90. The company has a quick ratio of 6.58, a current ratio of 6.58 and a debt-to-equity ratio of 0.24.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.11). During the same period in the prior year, the business posted ($0.46) EPS. Equities analysts expect that Scholar Rock Holding Co. will post -2.4 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on SRRK. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Scholar Rock in a research report on Tuesday, June 4th. BMO Capital Markets increased their price objective on shares of Scholar Rock from $29.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, June 13th. Wedbush reissued an “outperform” rating and set a $23.00 price objective on shares of Scholar Rock in a report on Tuesday, May 7th. Piper Sandler reissued an “overweight” rating and set a $28.00 price objective on shares of Scholar Rock in a report on Tuesday, March 26th. Finally, Truist Financial reissued a “buy” rating and set a $20.00 price objective on shares of Scholar Rock in a report on Wednesday, April 3rd. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $26.00.

Institutional Investors Weigh In On Scholar Rock

Several institutional investors have recently modified their holdings of SRRK. Polar Capital Holdings Plc acquired a new stake in shares of Scholar Rock during the 3rd quarter worth approximately $10,664,000. Price T Rowe Associates Inc. MD grew its position in shares of Scholar Rock by 16.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,321,471 shares of the company’s stock worth $156,444,000 after buying an additional 1,149,519 shares during the period. Eventide Asset Management LLC acquired a new stake in shares of Scholar Rock during the 4th quarter worth approximately $18,287,000. Goldman Sachs Group Inc. grew its position in shares of Scholar Rock by 31.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,430,764 shares of the company’s stock worth $26,898,000 after buying an additional 342,690 shares during the period. Finally, Redmile Group LLC grew its holdings in Scholar Rock by 7.5% during the third quarter. Redmile Group LLC now owns 4,733,248 shares of the company’s stock valued at $33,606,000 after purchasing an additional 329,408 shares during the period. Institutional investors and hedge funds own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.